- Upcoming drug approvals could boost shares
- Concerns linger over litigation and long-term pipeline
GSK (GSK) has reported better-than-anticipated revenue for 2022, thanks in significant part to its blockbuster Shingrix shingles vaccine. The pharma giant, which is working to emerge from years of share price underperformance, now expects adjusted operating profit to increase by between 10 and 12 per cent in 2023.